Abbott Laboratories $ABT Shares Sold by Strs Ohio

Strs Ohio trimmed its holdings in Abbott Laboratories (NYSE:ABT) by 3.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 544,394 shares of the healthcare product maker’s stock after selling 21,803 shares during the period. Strs Ohio’s holdings in Abbott Laboratories were worth $68,207,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Global Financial Private Client LLC increased its stake in Abbott Laboratories by 3.3% during the third quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after acquiring an additional 79 shares during the last quarter. Citizens & Northern Corp increased its stake in Abbott Laboratories by 0.4% during the third quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after acquiring an additional 79 shares during the last quarter. American National Bank of Texas increased its stake in Abbott Laboratories by 2.4% during the fourth quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock worth $427,000 after acquiring an additional 79 shares during the last quarter. Nia Impact Advisors LLC increased its stake in Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after acquiring an additional 79 shares during the last quarter. Finally, Nova R Wealth Inc. increased its stake in Abbott Laboratories by 3.0% during the third quarter. Nova R Wealth Inc. now owns 2,802 shares of the healthcare product maker’s stock worth $375,000 after acquiring an additional 81 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction on Monday, April 27th. The shares were acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have acquired 22,200 shares of company stock valued at $2,215,100 and have sold 3,055 shares valued at $353,097. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Price Performance

ABT stock opened at $89.51 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.18 and a current ratio of 1.39. Abbott Laboratories has a 1 year low of $89.14 and a 1 year high of $139.06. The firm has a market cap of $155.90 billion, a P/E ratio of 25.07, a price-to-earnings-growth ratio of 1.51 and a beta of 0.66. The stock has a 50-day simple moving average of $104.33 and a 200-day simple moving average of $116.20.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same quarter last year, the firm earned $1.09 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.8%. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

Wall Street Analysts Forecast Growth

ABT has been the subject of several research analyst reports. Citigroup dropped their price target on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Piper Sandler dropped their price target on Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Weiss Ratings lowered Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, April 24th. TD Cowen dropped their price target on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, Wells Fargo & Company dropped their price target on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $119.43.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.